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Background: The identification of malignant cells in effusions by conventional cytology is hampered by its limited
sensitivity and specificity. The aim of this study was to investigate the value of fluorescence in situ hybridization
(FISH) as adjuncts to conventional cytologic examination in patients with malignant pleural effusions.
Methods: We conducted a retrospective cohort study of 93 inpatients with pleural effusions (72 malignant pleural
effusions metastatic from 11 different organs and 21 benign) over 23 months. All the patients came from Chinese
northeast areas. Aspirated pleural fluid underwent cytologic examination and fluorescence in situ hybridization
(FISH) for aneuploidy. We used FISH in single-colour or if appropriate in dual-colour evaluation to detect
chromosomal aberrations (chromosomes 7, 11, and 17) in effusion cells as markers of malignancy, to raise the
diagnostic yield and identified the efficiency by diagnostic biopsy. Predominant cytogenetic anomalies and patterns
of intratumor cytogenetic heterogeneity were brought in relation to overall survival rate.
Results: Cytology alone confirmed malignant pleural effusions in 45 of 72 patients (sensitivity 63%), whereas FISH
alone positively identified 48 of 72 patients (sensitivity 67%). Both tests had high specificity in predicting benign
effusions. If cytology and FISH were considered together, they exhibited 88% sensitivity and 94.5% specificity in
discriminating benign and malignant effusions. Combined, the two assays were more sensitive than either test
alone. Although the positive predictive value of each test was 94.5%, the negative predictive value of cytology and
FISH combined was 78%, better than 47% and 44% for FISH and cytology alone, respectively. There was a
significantly prolonged survival rate for patients with aneuploidy for chromosome 17.
Conclusions: FISH in combination with conventional cytology is a highly sensitive and specific diagnostic tool for
detecting malignant cells in pleural effusions . The high sensitivity and specificity may be associated with
geographic area and race. Simple numeric FISH anomalies may be prognostic.
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Diagnosis of malignancy in pleural effusions from cancer
patients is frequently troublesome for the cytologist be-
cause the differentiation of malignant cells from accom-
panying elements such as atypical reactive mesothelial
cells is difficult [1]. On the other hand, in pleural effu-
sions tumour cells may appear quite similar to normal
cells, for example, small-cell lung cancer cells and lym-
phocytes [2]. Due to these difficulties, cytopathologists
traditionally adopt a rather cautious approach in the
diagnosis of malignancy in effusions. With a negative cy-
tology result in a patient with suspected malignant
pleural effusion, standard clinical practice involves a re-
peat thoracentesis, a pleural biopsy, or thoracoscopy to
prove the presence of tumor cells in the pleural fluid.
Thoracoscopy is effective in this regard and has a high
diagnostic yield for malignant disease involving the
pleura [3]. Nevertheless, the risks of additional diagnos-
tic procedures that are painful and invasive, such as
thoracoscopy, present a considerable clinical challenge.
Then new methods complementing cytology for the
diagnostic work-up of pleural effusion need to be
evaluated.
Genomic alterations are a hallmark of malignant cells.
In the resent years, interphase cytogenetics by fluores-
cence in situ hybridization (FISH) has been increasingly
used in clinical pathology to delineate chromosomal
aberrations in neoplasia [4-8]. Because carcinoma cells
are regularly characterized by extensive chromosomal
aberrations, FISH analysis can be used as a diagnostic
tool to detect aneuploid cells characterizing malignancy,
provided that cutoffs for background nondisomy are
considered. We performed tumour-associated aneu-
ploidy analyses on prospectively collected pleural fluids
in order to investigate if there was a complimentarity of
cytology and chromosomal aberrations assays in detect-
ing malignant tumor cells in the fluids. Overall survival
rate from the first diagnosis of malignancy until death or
final follow-up was evaluated. We hypothesized that
FISH would be able to detect patients with malignant
chromosomal aberrations in their pleural fluid and that,
used with cytology, they would enhance diagnosis.
Moreover, FISH may be associated with survival rate in
patients with malignant pleural effusions.
Methods
Clinical and pathologic features of the study population
Effusion sampling and investigation analyses had been
approved by the institutional ethics committee. The
study population comprised 93 patients with documen-
ted pleural effusions who underwent pleural fluid aspir-
ation for diagnostic purposes at The Fourth Affiliated
Hospital of Harbin Medical University between October
2008 and September 2011. All the patients were born inChinese north areas. The study was presented to the
Hospital Ethical Board and accepted as this is an obser-
vational study based on the best available evidence. The
research was conducted conformed to the Helsinki Dec-
laration and to local legislation. Patients gave informed
consent to participate in the study. Results of conven-
tional cytology and FISH analyses of the pleural fluids
from patients were compared with respect to the defini-
tive diagnosis established by either tissue biopsy, or
through clinical follow-up in the case of patients with
benign disease. Patients who were free of malignancy
had a median follow-up of 6.5 months (range, 1.2 to
32.4). The median age of the study population was 68
years (range, 23 to 85) and there was a predominance of
males (63 of 93, or 68%). Pleural invasion was defined as
invasion of tumor through either the parietal or visceral
pleura.
Pleural fluid was obtained either via a needle during
thoracentesis (42%), a chest tube during thoracostomy
(13%) or by aspiration through a 1-cm incision at the
very beginning of a thorascopic pleurodesis procedure
(45%). Aspirated pleural fluid was collected in sterile
tubes without anticoagulant and rapidly brought to The
Fourth Affiliated Hospital of Harbin Medical University
pathology laboratory for conventional cytologic exami-
nations as well as to the research laboratory where they
were analyzed by FISH.
Conventional cytology
About 100 cc of aspirated pleural fluid was spun in a
centrifuge at 2,160 rpm for 10 minutes, supernatant
removed, and the cell pellet both preserved onto glass
slides in ethanol for Papnicolau staining as well as in for-
malin and ethanol for processing into cellblocks as per
standard protocol in the hospital pathology laboratory.
The presence or absence of malignant cells in the cyto-
logic material was reported with the agreement of two
attending cytopathologistes.
Fluorescence in situ hybridisation analysis
Cells of at least 200 mL of effusion fluid were gained by
centrifugation, and, in case of macroscopic blood con-
tamination, subjected to density gradient separation over
Ficoll-Hypaque (Sigma, St Louis, MO). Pelleted effusion
cells were washed in phosphate-buffered saline, fixed in
methanol-acetic acid (3:1, v/v) and stored at −80°C. Dir-
ectly fluorescence-labeled alpha-satellite DNA probes
(SpectrumGreen [excitation peak of 497 nm, emission
peak of 524 nm] and SpectrumOrange [559 nm/588
nm]; Vysis Inc, Downers Grove; IL) were applied in
dual-color FISH experiments. The probes used in this
study were specific for the centromeres of chromosomes
7, 11, and 17. The standard protocol followed was
described in a previous report [9].
Table 2 Definitive Diagnosis of Patients in Study
Type of Primary Cancer, n=93 No. (%)
Nonsmall cell lung 39 (41.9)
Breast 9 (9.7)
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aneuploidy
A fluorescence microscope with × 60 and ×100 planar
objectives and appropriate filter sets was used for FISH
signal evaluation and documentation. All effusion cells
in a field except for polynucleated granulocytes, which
are easily distinguishable by nuclear shape, were ana-
lysed. The stringent criteria of FISH signal assessment
were applied to avoid overestimation of hyperdiploidy,
which may result from cellular and technical factors
[10]. Signal counting was performed by two investigators
and intraobserver, and interobserver counting variations
were evaluated repeatedly. In order to evaluate the fre-
quencies of aneusomic effusion cells with statistical reli-
ability, centromeric signals of 100–1000 nuclei were
scored, with high-number cell counting in samples with
a low frequency of aneuploidy [11]. When necessary, we
used a two-tiered scoring procedure: (1) in all 93 effu-
sions, scoring of nuclei in single-colour FISH evaluation
was performed, and if aneusomy above cutoff for any of
the tested chromosomes was present, malignancy could
be documented; otherwise, in step (2), scoring of
selected, namely hyperdisomic, nuclei was performed in
dual-colour FISH evaluation, which allowed for the de-
tection of rare FISH-aneuploid cells [12]. For unequivo-
cal identification of true aneuploidy representing
malignancy, stringent cutoff threshold levels for back-
ground nondisomy were applied. The resulting mean
percentages of aneusomy and standard deviations were
used to calculate chromosome-specific background cut-
off levels for aneusomy, which were applied in the study
presented here (Table 1). The mean percentages plus 3
standard deviations of control cells with 1, 3, 4, and
greater than 4 signals were taken as cutoffs (Table 1).
Test effusions were considered as aneuploid when the
percentages of nondiploid nuclei (categorized into cell
populations with 1, 3, 4, greater than 4 signals) exceeded
respective cutoff levels. In cases in which the diagnosis
of aneuploidy was based on a rate of combined aneu-
ploidy in less than 5% of cells, a repeated FISH experi-
ment using appropriate probes for reconfirmation was
performed.Table 1 Cutoff threshold levels for background aneusomy
(percentage) for the three chromosomes examined
Signal number category
1 3 4 >4
Chromosome 7 11.5 0.6 0.7 0.2
Chromosome 11 11.2 0.4 1.2 0.2
Chromosome17 13.4 0.9 1.0 0.1
The presented cutoffs were determined by evaluation of non-disomy in 15
nonmalignant control effusions, and reflect the mean+3 s.d. percentage of
aneusomic cells within each of four FISH signal categories.Statistical analysis
Sensitivity, specificity, positive predictive values and
negative predictive values of both FISH and conven-
tional cytology as well as of the combination of both
techniques were calculated in relation to the definitive
diagnosis of the patients in the study. Correlation be-
tween variables was estimated using the Fisher’s exact
test, or the χ2 test when appropriate. Survival time was
analyzed using the Kaplan-Meier method, and differ-
ences between two groups(exhibiting or not exhibiting
aneuploidy for chromosome 17) were evaluated with the
log-rank test. All P values are two-sided, and all signifi-
cant associations were considered when the P value was
0.05 or less. SSPS16.0 software was used for calculations.
Results
Of the 72 patients with malignancy as the definitive
diagnosis, the most frequent underlying tumour entities
were lung, breast, colon, ovarian (Table 2). Primary can-
cers from the lung and breast represented the over-
whelming majority of malignancies: 48 of 72 (67%).
Sensitivity, positive predictive value, and negative
predictive value of conventional cytology, fluorescence in
situ hybridisation, and the tests combined
Conventional cytology alone detected the presence of
neoplastic cells in 45 of 72 patients (sensitivity of 63%)
whereas no malignant cells were isolated from the
pleural fluid of benign patients (specificity of 90.2%;
P=0.006). Fluorescence in situ hybridisation analysis was
performed in single-colour FISH evaluation when aneus-
omy was present above a cutoff value, unambiguously
discriminating tumour-associated aneusomy from back-
ground ‘physiological’ aneusomy. When aneusomic cells
were rare, evaluation in dual-colour FISH evaluation was









Benign diseae 21 (22.6)
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Fluorescence in situ hybridisation analysis alone was
diagnostic for malignant cells in 48 out of 72 effusions
(sensitivity of 67%) while no patient with benign disease
had a positive test of their pleural fluid (specificity of
98.7%; P=0.002). If conventional cytology and FISH were
considered together, the two techniques showed comple-
mentarity increasing the sensitivity to 87.5% while main-
taining a specificity of 94.5% in discriminating benign
and malignant disease. The positive predictive value for
FISH alone, cytology alone, as well as the combination
of both techniques was over 90%. The negative predictor
value of cytology and FISH tests alone were 44% and
47%, respectively. The combination of both techniques
increased the negative predictor value to 78%.
Correlation of cytology and FISH analyses of pleural fluid
Although both cytology and FISH analysis were compar-
able in terms of sensitivity, the tests were independent
of each other. FISH identified 30 of 45 pleural fluid aspi-
rates (67%) that were positive by cytologic analysis. In
addition, Fluorescence in situ hybridisation detected the
presence of chromosomal aberrations in the fluid from
18 of 27 patients (67%) who had cytology negative aspi-
rates. In 9 patients (1 patient with acute myelocytic
leukemia, 1 with renal cell carcinoma, 2 with ovarian
carcinoma, 2 with skin carcinoma, and 3 with NSCLC),
cytology and FISH as a combined analysis failed to de-
tect malignant cells or chromosomal aberrations, re-
spectively. FISH had a better sensitivity in predicting the
presence of a malignant pleural effusion from a NSCLC
primary cancer than cytology (30 of 39, or 77%, versus
24 of 39, or 62%, respectively). Of those patients withFigure 1 Malignant pleural effusion (non-small cell lung cancer)
with dual-color FISH-stained tumor cells showing differing
distribution patterns of green and orange signals
(chromosomes 7 and 17, respectively), indicative of
intranuclear chromosomal complexity.breast cancers, cytology and FISH both were able to de-
tect malignant pleural effusions with sensitivities of over
90%.Transudative versus exudative pleural fluid
Data concerning the character of the pleural effusions
(transudative or exudative) was available on 69 patients
(74%). A transudate was defined by a protein concentra-
tion of <2.5 g dl-1 [13]. There were six transudative effu-
sions in the patients with a primary malignancy and
both cytology as well as molecular examination did not
discern in these specimens any malignant cells or
chromosomal aberrations respectively. There were also
51 exudative effusions in all, 9 of which were in patients
with no malignancy. The combined tests of FISH and
cytology were more accurately able to classify the exuda-
tive effusions as being malignant (33 of 42, or 79%) than
either cytology (24 of 42, or 57%) or FISH alone (27 of
42, or 64%).Analysis of prognosis of patients with malignant pleural
effusions
As shown in Figure 2, the overall two-year survival rates
for patients without exhibiting aneuploidy for chromo-
some 17 (76.4%; 55 of 72) were lower than those for
patients with exhibiting aneuploidy for chromosome 17
(25.6%; 17 of 72). This difference was statistically signifi-
cant (P =0.04; log-rank test).Figure 2 Overall survival rate of patients with effusion cells
exhibiting or not exhibiting aneuploidy for chromosome 17.
There was a significantly prolonged survival rate for patients with
aneuploidy for chromosome 17, which was always a gain of copy
number except for one patient who exhibited predominantly
monosomy 17.
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Molecular analysis of the pleural fluid of patients using
fluorescence in situ hybridisation to discriminate those
with benign and malignant pleural effusions has not
been well studied. We hypothesized that in patients
in whom malignant cells may not be detectable in
the pleural fluid by conventional cytology, tumour-
associated aneuploidy would be present in sufficient
quantities to be detected, and that the sensitivity of this
approach would improve the overall diagnostic sensitiv-
ity of conventional cytology. Our data show that even
for multiple tumor types, and with a limited cohort size,
we were able to improve the diagnostic performance of
cytologic analysis by measuring tumour-associated aneu-
ploidy in the pleural fluid. We employed a molecular
technique and observed that conventional cytology and
FISH analysis alone have similar sensitivities (63% and
67%, respectively), but that the sensitivity improves to
88% when the results of the FISH and cytology techni-
ques are combined. It is noteworthy that cytology ana-
lysis cost $60 for each case vs $625 of cytology analysis
combined with FISH. It has been proposed that the use
of tissue microarray for FISH might provide satisfactory
results with a markedly cost reduction.
Tumor cell detection in effusions can be significantly
improved by FISH and PCR techniques applying appro-
priate molecular markers. PCR method targeted at
tumor-specific genetic abnormalities could detect a
small number of cancer cells mixed within a large num-
ber of normal cells. This method offered considerable
promise for early diagnosis of malignant pleural effu-
sions and detection of tumor progression before clinic-
ally evident metastasis. However, the clinical application
has been limited so far. The primary limitation had been
the lack of suitable target genes common to most
tumors. The other limitation of RT-PCR is related to la-
boratory method per se.
FISH analysis for the diagnosis of malignancy is based
on the fact that tumor cells are regularly chromosomally
aberrant, mostly harboring complex polysomies for one
or multiple chromosomes. The methodical approach
used here is based on the previous observation that the
identification and quantification of aneuploidy by FISH
can be used as a sensitive and highly specific marker of
malignancy in metastatic cells [11,14-17]. We selected
chromosomes 7, 11, and 17 for this study, which were
found to be prognostic markers in malignant tumour
[18-21]. We chose to use a combination of probes to
these 3 chromosomes as the basis for our FISH test to
detect genetically abnormal pleural effusions. Although
we had tumors from 11 different organ sites, we
designed a broad panel of genes to detect primarily
breast and lung tumors since the most common malig-
nancies that metastasize to the pleural fluid are, in orderof frequency, lung and breast. Our chromosome panel
was successful in detecting breast and lung neo-
plasms with sensitivities of 100% and 75%, respectively.
Moreover, 15 of the 24 tumors that FISH alone failed to
detect were not covered by our panel, namely, 1 patient
with acute myelocytic leukemia, 1 with renal cell carcin-
oma, 1 with cervical, 1 with chrondrosarcoma, 2 gas-
tric,2 with ovarian, 2 with skin, 2 with colon and 3 with
NSCLC. Indeed, it will be a challenge to be borne out of
subsequent studies to determine how large of a panel
of chromosomes will be required to identify the variety
of neoplasms that metastasize to the pleural cavity.
The survival rate correlated predominant aneusomy
for chromosomes 11 has been previously reported in
breast cancer and NSCLC. For breast cancer, patients
with no exhibiting aneuploidy for chromosome 11 in
cancerous effusions had a significantly shorter overall
survival rate than did have patients who had aneuploidy
[18]. Other studies also found that poor prognosis was
associated with aneusomy of chromosome 17 in breast
cancer [22,23]. In the present work, our results were
consistent with the above-mentioned studies showing
that aneuploidy for chromosome 17 was associated with
poor prognosis in patients with malignant pleural effu-
sions. But survival rate was not found to correlate with
the predominant aneusomy for chromosomes 7 and 11.
We also observed in the present study that pleural
fluids positive by the combined FISH and cytology ana-
lysis correlated with pleural invasion. These data suggest
that there is a higher yield of malignant cells in the
pleural fluid after the pleura is invaded by tumor. This is
in agreement with recent studies performed using
pleural lavages during pulmonary resections which have
shown increased detection of positive pleural lavage cy-
tology when there is parietal pleura invasion by malig-
nancy [24]. Combined cytology and FISH analysis were
also more accurate in discerning exudative samples from
patients with a primary malignancy. In general, exuda-
tive malignant pleural effusions have higher cell counts,
lower glucose and pH levels, and are cytologically posi-
tive. But these criteria are far from absolute [25], and in
our dataset, cytologic analysis only detected 57% of ex-
udative pleural fluids from patients with a known pri-
mary malignancy compared with 64% for FISH alone
and 79% for the chromosome and cytology assays
combined.
Limitations of the present study include the small co-
hort size that precludes detailed analysis of specific
tumor subtypes. Only descriptive, observational conclu-
sions about the FISH analyses in patients with NSCLC
and breast cancer can be made. Second, only FISH tech-
nology with 3 probes were used in this study. The
patients mainly came from Chinese north areas. There-
fore, it is need more study in a large patient group and
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chromosome anomalies to specific tumors in large
population. Finally, the patients with benign disease in
this study only had 6 months of longitudinal follow-up
to determine if they remained cancer free. That is usu-
ally insufficient time to allow preneoplastic events to
progress to clinically detectable cancer. Despite our abil-
ity to detect tumour-associated aneuploidy in pleural
fluid, the sensitivity of this assay would most likely be
enhanced by designing separate chromosome panels for
tumors originating from specific organs. Chromosome
profiles of tumors from different organs do seem to be
distinct [26,27], but more validity studies are necessary
before these profiles can be optimized for routine clin-
ical diagnostic use. Improving the diagnostic perform-
ance of any test has the potential to alter medical
practice, even if, as in this case, it simply means elimin-
ating the need for repeated thoracentesis or other inva-
sive procedures to secure the diagnosis of metastatic
disease in a patient with a know primary tumor. Al-
though a more sensitive test to diagnose patients earlier
may have limited clinical value in extending survival in
patients with metastatic disease, this assay may have im-
portant diagnostic implications particularly in patients
who have unilateral pleural effusions as their principal
presenting clinical sign. It is conceivable that chromo-
some profiles of the pleural fluid could also be used to
identify the site of origin of the metastatic malignant
cells in the chest. But this technology requires much val-
idation before it becomes clinically widespread.Conclusion
In conclusion, this study shows the feasibility of detect-
ing tumour-associated aneuploidy from a variety of dif-
ferent malignancies in the pleural fluid of patients even
if conventional cytologic analyses are negative. In
addition, the FISH test may increase the sensitivity of
conventional cytology without a corresponding decrease
in specificity. The present results were obtained retro-
spectively and suggest that simple numeric FISH anom-
alies may be prognostic. Gainning of chromosome 17 in
malignant pleural effusions is a marker of superior prog-
nosis. This observation may prompt us to perform pro-
spective studies in which chromosomal changes in
malignancies will be correlated with survival rate. Larger
translational studies will be needed to validate that mo-
lecular markers may improve the diagnostic yield of the
current standard examination of pleural fluid.
Abbreviation
FISH: Fluorescence in situ hybridization.
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